[Retracted] Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study

Table 1

Comparison of general balance between groups (%).

Related factors	Observation group (n = 72)	Control group (n = 72)	t/χ^2	P
Average age (years)	52.34 ± 8.61	52.18 ± 2.54	0.151	＞0.05
Body mass index (kg/m^2)	24.78 ± 2.33	23.69 ± 2.56	2.672	＞0.05
Gender			1.039	＞0.05
Male	40 (55.56)	46 (63.89)
Female	32 (44.44)	26 (36.11)
Age distribution			0.516	＞0.05
30∼44 years	18 (25.00)	16 (22.22)
45∼59 years	22 (30.56)	26 (36.11)
60∼75 years	32 (44.44)	30 (41.67)
Clinical staging			0.113	＞0.05
III B period	40 (55.56)	42 (58.33)
IV period	32 (44.44)	30 (41.67)
Degree of differentiation			0.508	＞0.05
High differentiation	22 (30.56)	20 (27.78)
Middle differentiation	40 (55.56)	44 (61.11)
Low differentiation	10 (13.89)	8 (11.11)
Transfer site			0.154	＞0.05
Lymph node	56 (77.78)	54 (75.00)
Bone	16 (22.22)	18 (25.00)